Molecular Subtype
Triple-Negative Breast Carcinoma
CI-CAN-00008567TNBCExplore in graph →
417 active trials3 approved drugs8 evidence items
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00008567TNBCExplore in graph →
Clinical trials
950 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (168)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04638751 | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | suspended | — | 5,000 | Persephone BiosciencesINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02993068 | Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) | suspended | N/A | 5,200 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment |
| suspended |
| — |
| 10 |
| Laura KennedyOTHER |
| 1 |
| Aug 19, 2026 |
| clinicaltrials |
| NCT05673200 | Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer | suspended | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05967533 | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors | suspended | Phase 1 | 100 | University of California, DavisOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03002103 | A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer | suspended | Phase 3 | 420 | SynCore Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 26, 2023 | clinicaltrials |
| NCT04250818 | Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile | suspended | — | 20 | Texas Tech University Health Sciences Center, El PasoOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT03777579 | A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC | suspended | Phase 3 | 375 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 8, 2019 | clinicaltrials |
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials